The posttransplant care outlined in Core H supports intensive ambulatory treatment before and after allogeneic transplant for all patients treated according to protocols presented in all projects of this Program Project. This Core also provides assistance to referring physicians in long-term posttransplant management of pediatric transplant patients. The major objectives are (1) to improve ambulatory care of the allogeneic transplant recipient in the outpatient department in the center and in the home community, and (2) to improve the long-term quality of life for children after marrow transplantation. The first objective evaluates discharge home at day 60 (early discharge) of medically stable ambulatory patients to determine the outcome for patients treated at the transplant center and in the home community. Data regarding hospitalizations and health care utilization will be utilized to design ways to assist community providers in the care of posttransplant allogeneic recipients. For the second objective, improvements in long-term quality of life of children after transplant, a number of studies will be conducted including: (a) studies to improve the final adult height of children through early administration of growth hormone and/or sex hormone, (b) a longitudinal study of neuropsychological function and time of appearance of learning disabilities among children receiving different preparative regimens, (c) a study of the incidence and progression of pulmonary disease among children surviving greater than or equal to 5 years after transplant, and (d) a study of the quality of survival of adult survivors of a childhood marrow transplant to evaluate whether these individuals are comparable with adult survivors of an adult transplant. The goal of Core H is to improve posttransplant survival and quality of care of children through early diagnostic and interventive strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA018029-23
Application #
6268989
Study Section
Project Start
1997-12-22
Project End
1998-11-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
23
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Deegan, Anthony J; Talebi-Liasi, Faezeh; Song, Shaozhen et al. (2018) Optical coherence tomography angiography of normal skin and inflammatory dermatologic conditions. Lasers Surg Med 50:183-193
Leger, Kasey J; Baker, K Scott; Cushing-Haugen, Kara L et al. (2018) Lifestyle factors and subsequent ischemic heart disease risk after hematopoietic cell transplantation. Cancer 124:1507-1515
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Shaw, Bronwen E; Syrjala, Karen L; Onstad, Lynn E et al. (2018) PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 124:841-849
Jamani, Kareem; Onstad, Lynn E; Bar, Merav et al. (2018) Quality of Life of Caregivers of Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2271-2276
Ogimi, Chikara; Xie, Hu; Leisenring, Wendy M et al. (2018) Initial High Viral Load Is Associated with Prolonged Shedding of Human Rhinovirus in Allogeneic Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant 24:2160-2163
Salter, Alexander I; Pont, Margot J; Riddell, Stanley R (2018) Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood 131:2621-2629
Lee, Stephanie J; Nguyen, Tam D; Onstad, Lynn et al. (2018) Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:555-562
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313

Showing the most recent 10 out of 1845 publications